Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2021-09-08 Annual Report
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
110年年報及股東會資料 — 2021_1786_20210622F05.pdf
Annual Report Classification · 95% confidence The document contains detailed voting results tables, references to a shareholders' meeting (股東常會), and multiple mentions of audit committee reports (審計委員會查核報告書) for the fiscal year 109 (which corresponds to 2020 in the ROC calendar). It includes detailed financial data, audit opinions from Ernst & Young, and extensive accounting notes and disclosures. The presence of a comprehensive audit report integrated with the business report and dividend proposals, along with detailed financial statements and management discussion, indicates this is a full annual report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-09-08 Chinese
110年年報及股東會資料 — 2021_1786_20210622F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains detailed information about the top ten shareholders, their shareholdings, and relationships among them, including family ties and related party disclosures. It is a typical major shareholding notification showing ownership percentages and related party relationships as per accounting standards. The document is short (1417 characters) and focuses on shareholding details rather than financial results or management changes. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2021-09-08 Chinese
110年年報及股東會資料 — 2020_1786_20210622F04.zip
Regulatory Filings
2021-09-08 Chinese
110年年報及股東會資料 — 2021_1786_20210622F13.pdf
Annual Report Classification · 95% confidence The document is a detailed meeting manual and report for the Annual General Meeting (AGM) of Scivision Biotech Inc. It includes the agenda, procedures, and attachments such as the 109th fiscal year business report, audit committee's audit report, financial statements, profit distribution, and amendments to the company charter. The presence of detailed financial statements, audit reports, and business reports for the fiscal year 109 (which corresponds to 2020 in the Gregorian calendar) indicates this is a comprehensive annual report document. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-09-08 Chinese
110年年報及股東會資料 — 2021_1786_20210622F02.pdf
Annual Report Classification · 95% confidence The document is a detailed meeting manual and report for the Annual General Meeting (AGM) of Scivision Biotech Inc. It includes the agenda, procedures, reports such as the 109th fiscal year business report, audit committee's review report, financial statements, profit distribution proposals, and amendments to company bylaws. The presence of detailed financial statements, audit reports, and business performance analysis indicates this is a comprehensive yearly report covering company activity and full financial performance. The document is lengthy (15,000 characters) and contains substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-09-08 Chinese
110年年報及股東會資料 — 2021_1786_20210622F01.pdf
AGM Information Classification · 100% confidence The document is a detailed notice and related materials for the 110th Annual General Meeting (AGM) of the company 科妍生物科技股份有限公司. It includes the meeting date, location, agenda items such as approval of the 109th fiscal year business report and financial statements, dividend distribution, amendments to the company bylaws, and instructions for shareholders on proxy voting and attendance. There are no actual financial statements or detailed financial analysis included, only the meeting notice, proxy forms, dividend payment instructions, and procedural information. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length (5528 characters) and content confirm it is not a full Annual Report or Interim Report, nor is it a simple announcement of a report publication. Therefore, the classification is AGM Information (AGM-R).
2021-09-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.